Payment overview · 2025
General Payments
$967.03
41 reported records · 16 companies
Healthcare provider profile · identity verified
Luis C Devenecia, MD
Allopathic & Osteopathic Physicians|Internal Medicine · OLNEY, IL · NPI 1750495792
Verified facts
What the public records show
CMS Open Payments records show Luis C Devenecia, MD received $967.03 in general payments during 2025 across 41 reported records.
AstraZeneca Pharmaceuticals LP accounted for 38.3% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 23 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Farxiga, Jardiance, Mounjaro, Ozempic.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 61 claims for Synthroid by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 196 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 39 claims for Symbicort by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 192 claims for Jardiance by this doctor in 2024.
Janssen Pharmaceuticals, Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported XARELTO as an associated drug or biological on 28 records involving 28 distinct recipient NPIs. Public Medicare Part D data also shows 177 claims for Xarelto by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 192 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 90 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 43 claims for Trulicity by this doctor in 2024.
Novartis Pharmaceuticals Corporation reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ENTRESTO as an associated drug or biological on 9346 records involving 6254 distinct recipient NPIs. Public Medicare Part D data also shows 32 claims for Entresto by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 233 claims for Ozempic by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 364 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Paxlovid by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $369.94 | 38.3% | 10 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $107.37 | 11.1% | 6 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $84.73 | 8.8% | 4 | 2025 |
| Viatris Specialty LLC | Unresolved — no canonical attribution shown | $69.60 | 7.2% | 4 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $55.05 | 5.7% | 3 | 2025 |
| Braeburn Inc. | Unresolved — no canonical attribution shown | $50.12 | 5.2% | 2 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $41.27 | 4.3% | 2 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $37.59 | 3.9% | 2 | 2025 |
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $34.29 | 3.5% | 1 | 2025 |
| Hologic Sales and Service, LLC | Unresolved — no canonical attribution shown | $22.01 | 2.3% | 1 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $18.56 | 1.9% | 1 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $17.02 | 1.8% | 1 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $16.05 | 1.7% | 1 | 2025 |
| Janssen Pharmaceuticals, Inc | Unresolved — no canonical attribution shown | $15.44 | 1.6% | 1 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $14.21 | 1.5% | 1 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $13.78 | 1.4% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $967.03 | 41 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $211.99 | 2 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $125.13 | 6 | 2025 |
Source payment records
|
|||||
| LEQVIO Normalized: leqvio |
Drug | Novartis Pharmaceuticals Corporation | $84.73 | 4 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc., Lilly USA, LLC | $77.64 | 4 | 2025 |
Source payment records
|
|||||
| YUPELRI Normalized: yupelri |
Drug | Viatris Specialty LLC | $69.60 | 4 | 2025 |
Source payment records
|
|||||
| BRIXADI Normalized: brixadi |
Drug | Braeburn Inc. | $50.12 | 2 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $48.71 | 2 | 2025 |
Source payment records
|
|||||
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $34.29 | 1 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $27.02 | 1 | 2025 |
Source payment records
|
|||||
| APTIMA Normalized: aptima |
Device | Hologic Sales and Service, LLC | $22.01 | 1 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $21.99 | 1 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $18.56 | 1 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $17.91 | 1 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $17.91 | 1 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Otsuka America Pharmaceutical, Inc. | $17.02 | 1 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $16.05 | 1 | 2025 |
Source payment records
|
|||||
| SPRAVATO Normalized: spravato |
Drug | Janssen Pharmaceuticals, Inc | $15.44 | 1 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $15.00 | 1 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $15.00 | 1 | 2025 |
Source payment records
|
|||||
| VIBERZI Normalized: viberzi |
Drug | ABBVIE INC. | $14.25 | 1 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $14.21 | 1 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $14.21 | 1 | 2025 |
Source payment records
|
|||||
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $13.78 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 364 | exact normalized | Medicare Part D |
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 196 | exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 192 | exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 90 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 233 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
61 | 11 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
196 | 29 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
39 | suppressed by CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
192 | 29 |
| Janssen Pharmaceuticals, Inc Exact reporting entity; no affiliate inference |
2025 | XARELTO open payments reported associated product |
CMS Open Payments — General Payments 28 supporting records · 28 recipient NPIs · example record 1174296970 |
Xarelto · 2024 Exact normalized brand match · 1 Part D row |
177 | 22 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
192 | 29 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
90 | 18 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
43 | suppressed by CMS |
| Novartis Pharmaceuticals Corporation Exact reporting entity; no affiliate inference |
2025 | ENTRESTO open payments reported associated product |
CMS Open Payments — General Payments 9346 supporting records · 6254 recipient NPIs · example record 1200004797 |
Entresto · 2024 Exact normalized brand match · 1 Part D row |
32 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
233 | 40 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
364 | 55 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
12 | 12 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Amlodipine Besylate | Amlodipine Besylate | 942 | 198 |
| Levothyroxine Sodium | Levothyroxine Sodium | 835 | 153 |
| Atorvastatin Calcium | Atorvastatin Calcium | 723 | 154 |
| Omeprazole | Omeprazole | 633 | 134 |
| Lisinopril | Lisinopril | 602 | 122 |
| Losartan Potassium | Losartan Potassium | 574 | 118 |
| Metoprolol Succinate | Metoprolol Succinate | 446 | 93 |
| Tramadol Hcl | Tramadol Hcl | 430 | 88 |
| Hydrochlorothiazide | Hydrochlorothiazide | 420 | 95 |
| Furosemide | Furosemide | 419 | 91 |
| Potassium Chloride | Potassium Chloride | 411 | 97 |
| Metformin Hcl Er | Metformin Hcl | 385 | 75 |
| Carvedilol | Carvedilol | 379 | 72 |
| Duloxetine Hcl | Duloxetine Hcl | 364 | 64 |
| Eliquis | Apixaban | 364 | 55 |
| Pravastatin Sodium | Pravastatin Sodium | 355 | 79 |
| Gabapentin | Gabapentin | 318 | 63 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 315 | 68 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 297 | 38 |
| Pantoprazole Sodium | Pantoprazole Sodium | 284 | 59 |
| Warfarin Sodium | Warfarin Sodium | 278 | 27 |
| Fluticasone Propionate | Fluticasone Propionate | 259 | 101 |
| Escitalopram Oxalate | Escitalopram Oxalate | 245 | 42 |
| Tamsulosin Hcl | Tamsulosin Hcl | 243 | 48 |
| Ozempic | Semaglutide | 233 | 40 |
| Donepezil Hcl | Donepezil Hcl | 230 | 33 |
| Mirtazapine | Mirtazapine | 225 | 39 |
| Montelukast Sodium | Montelukast Sodium | 223 | 47 |
| Farxiga | Dapagliflozin Propanediol | 196 | 29 |
| Ropinirole Hcl | Ropinirole Hcl | 193 | 29 |
| Jardiance | Empagliflozin | 192 | 29 |
| Spironolactone | Spironolactone | 182 | 38 |
| Memantine Hcl | Memantine Hcl | 179 | 26 |
| Xarelto | Rivaroxaban | 177 | 22 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 170 | 54 |
| Hydralazine Hcl | Hydralazine Hcl | 167 | 31 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 156 | 31 |
| Allopurinol | Allopurinol | 150 | 34 |
| Metoprolol Tartrate | Metoprolol Tartrate | 143 | 35 |
| Clopidogrel | Clopidogrel Bisulfate | 141 | 27 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 137 | 22 |
| Meloxicam | Meloxicam | 134 | 31 |
| Famotidine | Famotidine | 131 | 27 |
| Atenolol | Atenolol | 130 | 29 |
| Doxazosin Mesylate | Doxazosin Mesylate | 124 | 32 |
| Simvastatin | Simvastatin | 120 | 24 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 119 | 23 |
| Trazodone Hcl | Trazodone Hcl | 118 | 21 |
| Buspirone Hcl | Buspirone Hcl | 117 | 27 |
| Alprazolam | Alprazolam | 110 | 21 |
| Citalopram Hbr | Citalopram Hydrobromide | 90 | 15 |
| Mounjaro | Tirzepatide | 90 | 18 |
| Ezetimibe | Ezetimibe | 88 | 20 |
| Azithromycin | Azithromycin | 87 | 67 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 85 | 16 |
| Cephalexin | Cephalexin | 80 | 56 |
| Prednisone | Prednisone | 77 | 41 |
| Finasteride | Finasteride | 72 | 16 |
| Glipizide | Glipizide | 70 | 15 |
| Glipizide Er | Glipizide | 70 | 16 |
| Amiodarone Hcl | Amiodarone Hcl | 69 | 15 |
| Azelastine Hcl | Azelastine Hcl | 69 | 26 |
| Glimepiride | Glimepiride | 68 | 19 |
| Sertraline Hcl | Sertraline Hcl | 68 | 15 |
| Propranolol Hcl | Propranolol Hcl | 66 | suppressed |
| Lorazepam | Lorazepam | 65 | 15 |
| Metformin Hcl | Metformin Hcl | 65 | 18 |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 65 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 63 | 13 |
| Synthroid | Levothyroxine Sodium | 61 | 11 |
| Benazepril Hcl | Benazepril Hcl | 59 | 11 |
| Levetiracetam | Levetiracetam | 59 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 58 | 13 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 57 | 16 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 56 | 15 |
| Myrbetriq | Mirabegron | 54 | suppressed |
| Januvia | Sitagliptin Phosphate | 53 | 13 |
| Pregabalin | Pregabalin | 50 | suppressed |
| Theophylline Er | Theophylline Anhydrous | 50 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 48 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 46 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 45 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 43 | 12 |
| Klor-Con M20 | Potassium Chloride | 43 | 15 |
| Novolog Flexpen | Insulin Aspart | 43 | 14 |
| Trulicity | Dulaglutide | 43 | suppressed |
| Latanoprost | Latanoprost | 42 | suppressed |
| Tradjenta | Linagliptin | 41 | suppressed |
| Valsartan | Valsartan | 41 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 39 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 39 | suppressed |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 39 | suppressed |
| Bupropion Xl | Bupropion Hcl | 36 | suppressed |
| Celecoxib | Celecoxib | 36 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 36 | suppressed |
| Fenofibrate | Fenofibrate,micronized | 36 | suppressed |
| Lactulose | Lactulose | 34 | suppressed |
| Olanzapine | Olanzapine | 34 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 34 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 33 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 33 | 11 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 32 | 26 |
| Doxycycline Hyclate | Doxycycline Hyclate | 32 | 19 |
| Entresto | Sacubitril/Valsartan | 32 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 31 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 31 | suppressed |
| Risperidone | Risperidone | 30 | suppressed |
| Incruse Ellipta | Umeclidinium Bromide | 29 | suppressed |
| Ondansetron Odt | Ondansetron | 29 | 15 |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 29 | suppressed |
| Ultra-Fine Nano Pen Needle | Pen Needle, Diabetic | 29 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 28 | suppressed |
| Fiasp Flextouch | Insulin Aspart (Niacinamide) | 28 | suppressed |
| Irbesartan | Irbesartan | 28 | suppressed |
| Novolog | Insulin Aspart | 27 | suppressed |
| Colesevelam Hcl | Colesevelam Hcl | 26 | suppressed |
| Gemfibrozil | Gemfibrozil | 26 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 24 | 17 |
| Cefdinir | Cefdinir | 23 | 17 |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 23 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 23 | 11 |
| Admelog Solostar | Insulin Lispro | 22 | suppressed |
| Dropsafe Pen Needle | Pen Needle, Diabetic, Safety | 22 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 22 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 22 | suppressed |
| Timolol Maleate | Timolol Maleate | 22 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 22 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 21 | suppressed |
| Cinacalcet Hcl | Cinacalcet Hcl | 21 | suppressed |
| Diltiazem 24hr Er | Diltiazem Hcl | 21 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 21 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 21 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 21 | 18 |
| Nystatin | Nystatin | 21 | 15 |
| Ondansetron Hcl | Ondansetron Hcl | 21 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 21 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 20 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 20 | suppressed |
| Lovastatin | Lovastatin | 20 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 20 | suppressed |
| Nitroglycerin | Nitroglycerin | 20 | 18 |
| Fluconazole | Fluconazole | 19 | 16 |
| Lansoprazole | Lansoprazole | 19 | suppressed |
| Levofloxacin | Levofloxacin | 19 | 17 |
| Propranolol Hcl Er | Propranolol Hcl | 19 | suppressed |
| Digoxin | Digoxin | 18 | suppressed |
| Levemir Flexpen | Insulin Detemir | 18 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 18 | suppressed |
| Dilt-Xr | Diltiazem Hcl | 17 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 17 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 16 | suppressed |
| Spiriva Handihaler | Tiotropium Bromide | 16 | suppressed |
| Unifine Safecontrol Pen Needle | Pen Needle,dual Safety,diabetc | 16 | suppressed |
| Combivent Respimat | Ipratropium/Albuterol Sulfate | 15 | suppressed |
| Diltiazem 12hr Er | Diltiazem Hcl | 15 | suppressed |
| Methylprednisolone | Methylprednisolone | 15 | 13 |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 15 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 14 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 14 | suppressed |
| Amantadine | Amantadine Hcl | 13 | suppressed |
| Carbamazepine | Carbamazepine | 13 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 13 | suppressed |
| Diazepam | Diazepam | 13 | suppressed |
| Memantine Hcl Er | Memantine Hcl | 13 | suppressed |
| Nifedipine Er | Nifedipine | 13 | suppressed |
| Novolog Mix 70-30 Flexpen | Insulin Aspart Prot/Insuln Asp | 13 | suppressed |
| Primidone | Primidone | 13 | suppressed |
| Repatha Sureclick | Evolocumab | 13 | suppressed |
| Sucralfate | Sucralfate | 13 | suppressed |
| Trandolapril | Trandolapril | 13 | suppressed |
| Acyclovir | Acyclovir | 12 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 12 | suppressed |
| Dofetilide | Dofetilide | 12 | suppressed |
| Ibandronate Sodium | Ibandronate Sodium | 12 | suppressed |
| Isosorbide Dinitrate | Isosorbide Dinitrate | 12 | suppressed |
| Mesalamine Er | Mesalamine | 12 | suppressed |
| Methimazole | Methimazole | 12 | suppressed |
| Mycophenolate Mofetil | Mycophenolate Mofetil | 12 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 12 | 12 |
| Prochlorperazine Maleate | Prochlorperazine Maleate | 12 | suppressed |
| Ramipril | Ramipril | 12 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 11 | suppressed |
| Alprazolam Er | Alprazolam | 11 | suppressed |
| Ammonium Lactate | Ammonium Lactate | 11 | suppressed |
| Cholestyramine | Cholestyramine (With Sugar) | 11 | suppressed |
| Clotrimazole | Clotrimazole | 11 | suppressed |
| Dupixent Syringe | Dupilumab | 11 | suppressed |
| Glucagon Emergency Kit | Glucagon | 11 | suppressed |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 11 | suppressed |
| Letrozole | Letrozole | 11 | suppressed |
| Novolin N | Insulin Nph Human Isophane | 11 | suppressed |
| Novolog Mix 70-30 | Insulin Aspart Prot/Insuln Asp | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $967.03 · 41 records | AstraZeneca Pharmaceuticals LP | AIRSUPRA, APTIMA, BREZTRI, BRIXADI, CAPLYTA, Dexcom G6 Transmitter, ELIQUIS, FARXIGA, JARDIANCE, Kerendia, LEQVIO, MOUNJARO, NURTEC ODT, Ozempic, REXULTI, Rybelsus, SPRAVATO, VIBERZI, VRAYLAR, Wegovy, XIFAXAN, YUPELRI, ZEPBOUND | 12 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error